Form 8-K - Current report:
SEC Accession No. 0001558370-25-004080
Filing Date
2025-03-31
Accepted
2025-03-31 08:01:09
Documents
14
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20250331x8k.htm   iXBRL 8-K 33131
2 EX-99.1 kala-20250331xex99d1.htm EX-99.1 119996
  Complete submission text file 0001558370-25-004080.txt   281513

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20250331.xsd EX-101.SCH 3263
4 EX-101.LAB kala-20250331_lab.xml EX-101.LAB 15268
5 EX-101.PRE kala-20250331_pre.xml EX-101.PRE 9660
16 EXTRACTED XBRL INSTANCE DOCUMENT kala-20250331x8k_htm.xml XML 4674
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 25788990
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)